Henrik Hoel

Henrik Hoel

Auto-generated profile, based on publicly available information

Henrik Hoel

Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2021 in Journal of Vascular Surgery
Verified
Journal Article
Open access
HHHenrik Hoel
Henrik Hoel
EPErik Mulder Pettersen
Erik Mulder Pettersen
LHLars Øivind Høiseth
Lars Øivind Høiseth
IMIacob Mathiesen
Iacob Mathiesen
ASArne Seternes
Arne Seternes
JHJonny Hisdal
Jonny Hisdal
We investigated the effects of lower extremity intermittent negative pressure (INP) treatment for 1 hour two times daily for 12 weeks on the walking distance of patients with intermittent claudication (IC). Patients with IC were randomized to treatment with -40 mm Hg INP (treatment group) or -10 mm Hg INP (sham control group). Pain-free walking distance (PWD) and maximal walking distance (MWD) on a treadmill, resting and postexercise ankle-brachial index, resting and postischemic blood flow (plethysmography), and quality of life (EQ-5D-5L and Vascuqol-6) were measured at baseline and after 12 weeks of treatment. A total of 72 patients were randomized, and 63 had data available for the intention-to-treat analyses. The between-group comparisons showed a significant change in the PWD, favoring the treatment group over the sham control group (estimated treatment effect, 50 m; 95% confidence interval [CI], 11-89; P = .014). The PWD had increased by 68 m (P < .001) in the treatment group and 18 m (P = .064) in the sham control group. No significant difference was found in the change in the MWD between the two groups (estimated treatment effect, 42 m; 95% CI, -14 to 97; P = .139). The MWD had increased by 62 m (P = .006) in the treatment group and 20 m (P = .265) in the sham control group. For patients with a baseline PWD of <200 m (n = 56), significant changes had occurred in both PWD and MWD between the two groups, favoring the treatment group (estimated treatment effect, 42 m; 95% CI, 2-83; P = .042; and estimated treatment effect, 62 m; 95% CI, 5-118; P = .032; respectively). Both overall and for the group of patients with a PWD <200 m, no significant differences were found in the changes in the resting and postexercise ankle-brachial index, resting and postischemic blood flow, or quality of life parameters between the two groups. Treatment with -40 mm Hg INP increased the PWD compared with sham treatment in patients with IC. For the patients with a baseline PWD of <200 m, an increase was found in both PWD and MWD compared with sham treatment.

20 October 2019 in Physiological Reports
Verified
Journal Article
Open access
PDF file
HHHenrik Hoel
Henrik Hoel
LHLars Øivind Høiseth
Lars Øivind Høiseth
GSGunnar Sandbæk
Gunnar Sandbæk
JSJon Otto Sundhagen
Jon Otto Sundhagen
IMIacob Mathiesen
Iacob Mathiesen
JHJonny Hisdal
Jonny Hisdal
Intermittent negative pressure applied to the lower leg induces acute increase in blood flow in patients with peripheral artery disease. Intermittent negative pressure of −40 mmHg was the lowest nega...

1 August 2021 in Annals of Vascular Surgery
Verified
Journal Article
Open access
HHHenrik Hoel
Henrik Hoel
EPErik Mulder Pettersen
Erik Mulder Pettersen
LHLars Øivind Høiseth
Lars Øivind Høiseth
IMIacob Mathiesen
Iacob Mathiesen
ASArne Seternes
Arne Seternes
JHJonny Hisdal
Jonny Hisdal
Background: Treatment with lower extremity intermittent negative pressure (INP) of-40 mm Hg for one hour twice daily for 12 weeks, increases walking capacity in patients with intermittent claudication (IC). However, the effects of INP treatment beyond 12 weeks have not been elucidated. The aim of the present study was to investigate the clinical effects of INP treatment after 24 weeks in patients with IC. Methods: This was a follow-up study after a randomized sham-controlled trial, where patients randomized to the active treatment group were offered to continue treatment for 12 additional weeks (24 weeks in total). Treatment with-40 mm Hg INP was applied in a pressure chamber sealed around the lower leg, and the patients were instructed to treat themselves at home one hour in the morning and one hour in the evening. Pain free walking distance (PWD), maximal walking distance (MWD), resting ankle-brachial index (ABI) and post exercise ABI were measured at baseline, after 12 and 24 weeks. Results: Ten out of 32 patients (31%) from the active treatment group in the initial trial were included in this follow-up study. At baseline, PWD was (mean +/- SD) 151 +/- 91 m and MWD was 362 +/- 159 m. There was a significant increase in both PWD and MWD after 24 weeks of treatment, compared to baseline (ANOVA; P = 0.006 and P = 0.012, respectively). Post hoc tests revealed that PWD increased significantly from baseline to 12 weeks (mean 81 m; 95% CI [6, 156]; P = 0.032), and that MWD increased significantly from 12 to 24 weeks (mean 145 m; 95% CI [22, 268]; P = 0.018). There were no significant changes in resting ABI or post exercise ABI during the 24-week treatment period (ANOVA; P = 0.157 and P = 0.450, respectively). Conclusion: Both PWD and MWD improved after treatment with - 40 mm Hg INP for one hour twice daily for 24 weeks, compared to baseline. The main improvement in PWD occurred during the first 12 weeks of treatment, whereas the main improvement in MWD occurred between 12 and 24 weeks of treatment.

14 January 2021 in PLOS ONE
Verified
Journal Article
Open access
PDF file
VEVictory ‘sEgun Ezeofor
Victory ‘sEgun Ezeofor
NBNathan Bray
Nathan Bray
LBLucy Bryning
Lucy Bryning
FHFarina Hashmi
Farina Hashmi
HHHenrik Hoel
Henrik Hoel
RERhiannon Tudor Edwards
Rhiannon Tudor Edwards
Background: Critical limb ischaemia is a severe stage of lower limb peripheral artery disease which can lead to tissue loss, gangrene, amputation and death. FlowOx™ therapy is a novel negative-pressure chamber system intended for home use to increase blood flow, reduce pain and improve wound healing for patients with peripheral artery disease and critical limb ischaemia. Methods: A Markov model was constructed to assess the relative cost-effectiveness of FlowOx™ therapy compared to standard care in lower limb peripheral artery disease patients with intermittent claudication or critical limb ischaemia. The model used data from two European trials of FlowOx™ therapy and published evidence on disease progression. From an NHS analysis perspective, various FlowOx™ therapy scenarios were modelled by adjusting the dose of FlowOx™ therapy and the amount of other care received alongside FlowOx™ therapy, in comparison to standard care. Results: In the base case analysis, consisting of FlowOx™ therapy plus nominal care, the cost estimates were £12,704 for a single dose of FlowOx™ therapy per annum as compared with £15,523 for standard care. FlowOx™ therapy patients gained 0.27 additional quality adjusted life years compared to standard care patients. This equated to a dominant incremental cost-effectiveness ratio per QALY gained. At the NICE threshold WTP of £20,000 and £30,000 per QALY gained, FlowOx™ therapy in addition to standard care had a 0.80 and 1.00 probability of being cost-effectiveness respectively. Conclusions: FlowOx™ therapy delivered as a single annual dose may be a cost-effective treatment for peripheral artery disease. FlowOx™ therapy improved health outcomes and reduced treatment costs in this modelled cohort. The effectiveness and cost-effectiveness of FlowOx™ therapy is susceptible to disease severity, adherence, dose and treatment cost. Research assessing the impact of FlowOx™ therapy on NHS resource use is needed in order to provide a definitive economic evaluation.

13 May 2021 in Vascular Medicine
Verified
Journal Article
Open access
PDF file
HHHenrik Hoel
Henrik Hoel
EPErik Mulder Pettersen
Erik Mulder Pettersen
LHLars Øivind Høiseth
Lars Øivind Høiseth
IMIacob Mathiesen
Iacob Mathiesen
ASArne Seternes
Arne Seternes
JHJonny Hisdal
Jonny Hisdal
The aim of this study was to investigate the effects of lower extremity intermittent negative pressure (INP) treatment for 1 hour twice daily for 12 weeks, on circulating vascular biomarkers in patients with intermittent claudication. Patients were randomized to treatment with –40 mmHg INP (treatment group), or –10 mmHg INP (sham control group). Venous blood samples were collected at baseline and after 12 weeks, and concentrations of vascular adhesion molecule-1 (VCAM-1), intracellular adhesion molecule-1 (ICAM-1), E-selectin, P-selectin, von Willebrand factor (vWF), l-arginine, asymmetric dimethylarginine (ADMA), and symmetric dimethylarginine (SDMA) were analyzed. A larger proportion of the patients in the treatment group (25/31) had a reduction in vWF levels after 12 weeks, compared to the sham control group (17/30) (p = 0.043). Within the treatment group there was a significant mean (SEM) reduction in the concentration of vWF of –11% (4) (p = 0.019), whereas there was no significant change in the levels of vWF in the sham control group (1% (6); p = 0.85). There were no significant differences in the change of any of the biomarker levels between the groups after 12 weeks of treatment. In conclusion, there were no differences in the change of the circulating levels of the measured biomarkers between the treatment group and the sham control group after 12 weeks of INP treatment. However, the observed changes in vWF might indicate a beneficial effect of INP treatment on endothelial activation and endothelial injury. Clinicaltrials.gov Identifier: NCT03640676

8 July 2025 in Annals of Vascular Surgery
Verified
Journal Article
Open access
NBNadja Buric
Nadja Buric
SMSaira Mauland Mansoor
Saira Mauland Mansoor
TLTormod Lund
Tormod Lund
HHHenrik Hoel
Henrik Hoel
Incisional hernias after open abdominal aortic aneurysm (AAA) repair can cause significant morbidity and affect quality of life. The aim of this study was to investigate the incidence of incisional hernias after elective open aortic or iliac artery aneurysm (IAA) repair, and to identify risk factors for incisional hernia development. This was a retrospective cohort study including patients who underwent elective open repair for AAA/IAA at the Department of Vascular Surgery, Oslo University Hospital, from 2010 to 2022. Data on patient characteristics and surgery related factors were collected from the medical records. Postoperative incisional hernias were registered if detected either on clinical examination or on postoperative computed tomography (CT) scans. In total, 298 patients were included, and 160/298 patients (54%) had postoperative CT scans available. Median follow-up time was 8.5 (interquartile range 6.5) years. A total of 85/298 (29%) incisional hernias were detected. Clinically detected incisional hernias constituted 56/298 (19%); of which, 31/56 (55%) were reported to be symptomatic and 8/56 (14%) had undergone hernia repair. Body mass index (BMI) was the only independent variable that was significantly associated with the development of incisional hernia (odds ratio 1.10; 95% confidence interval (1.03, 1.18); P = 0.007). Incisional hernias after open AAA/IAA repair were common, but few were symptomatic, and very few underwent hernia repair. BMI was a significant risk factor for the development of incisional hernia.